pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Eslicarbazepine Acetate
drug
save

eslicarbazepine acetate

Marketedupdated 2mo ago
by Shanghai Zhongxi Pharmaceutical Co Ltd
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagApproval2 co-mentions · 1 sources
  • tagSmall Molecule1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying eslicarbazepine acetate

  • phase3Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsycompletedn=395
  • phase3Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizurescompletedn=402

Patent cliff

source: FDA Orange Book
first barrier falls
Sep 13, 2028
~2.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (28)

  • Aug 24, 2032method-of-use (U-2121)US 9750747
  • Aug 24, 2032method-of-use (U-2041)US 9750747
  • Aug 24, 2032method-of-use (U-2121)US 9750747
  • Aug 24, 2032method-of-use (U-2041)US 9750747
  • Apr 17, 2030formulationUS 83724313.7y
  • Apr 17, 2030formulationUS 83724313.7y
  • Apr 17, 2030formulationUS 83724313.7y
  • Apr 17, 2030formulationUS 83724313.7y
  • Oct 23, 2028formulationUS 109127812.2y
  • Oct 23, 2028formulationUS 109127812.2y
  • Oct 23, 2028formulationUS 109127812.2y
  • Oct 23, 2028formulationUS 109127812.2y
  • Oct 23, 2028formulationUS 95662442.2y
  • Oct 23, 2028formulationUS 95662442.2y
  • Oct 23, 2028formulationUS 95662442.2y
  • Oct 23, 2028formulationUS 95662442.2y
  • Sep 13, 2028method-of-use (U-2123)US 97639542.1y
  • Sep 13, 2028method-of-use (U-2123)US 97639542.1y
  • Sep 13, 2028method-of-use (U-2123)US 97639542.1y
  • Sep 13, 2028method-of-use (U-2123)US 97639542.1y
  • Apr 21, 2026compositionUS 9206135
  • Apr 21, 2026compositionUS 9206135
  • Apr 21, 2026compositionUS 9206135
  • Apr 21, 2026compositionUS 9206135
  • Apr 21, 2026formulationUS 9643929
  • Apr 21, 2026formulationUS 9643929
  • Apr 21, 2026formulationUS 9643929
  • Apr 21, 2026formulationUS 9643929

News(0)

no news has mentioned this drug yet

brand
Eslicarbazepine Acetate
generic
eslicarbazepine acetate
indication
Partial Seizure
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 19m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?